By binding the substance to a radiotracer, experts were able to improve the accuracy of identifying these tumors by as much as 30% compared to the standard of care.
The premixed embolic agent is designed to embolize hypervascular tumors and occlude blood flow in a patient's peripheral blood vessels. It was recalled in April due to safety concerns.
The news comes just days after CMS confirmed these technologies would start receiving expanded Medicare coverage in November. HeartFlow and other AI vendors have already shared their excitement over the decision.
The supply of Mo-99 and Tc-99m—the most commonly utilized medical isotopes in the world—could be cut by as much as 40% until the reactor in the Netherlands is up and running again.
iCardio.ai, co-founded by a cardiologist, is part of the Cedars-Sinai Accelerator program. The startup has already announced new partnerships with Viz.ai, Abbott and others in the cardiac health space.
Four of the seven Medicare Administrative Contractors (MACs) announced they will now cover artificial intelligence-enabled quantitative coronary tomography (AI-QCT) and coronary plaque analysis (AI-CPA).
Baxter’s North Cove manufacturing site was significantly impacted by unprecedented rain and storm surge from Hurricane Helene hitting western North Carolina.
